Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Denmark: Novo Nordisk has announced that Lars Fruergaard Jorgensen will step down from his role as CEO of Novo Nordisk. He ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

As Lars Fruergaard Jørgensen steps, Novo Nordisk seeks new leadership while production hurdles impact the competitive ...

Novo Nordisk, Lars Fruergaard Jørgensen will step down from his position as Chief Executive Officer (CEO). He has been in ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

Novo Nordisk CEO Lars Fruergaard Jørgensen, who led the Danish drugmaker to new heights through its development of powerful medicines for diabetes and obesity, will step down from his position, the ...